HTFL

Analyst Note: HTFL (Heartflow, Inc.)

Date: 2026-06-20 Price: $33.64

1. Structural Readiness

State: Context-only Conservative Entry: — Current Price: $33.64 Extension: — ATR at Breakout: — ATR Current: 5.9% (High) Pivot Strength: — Cap Bucket: —

Setup Classification: The structural setup is currently FORMING.

2. Thesis Layer

Thesis Status: TACTICAL / Setup-Led Macro Thesis: None. Analysis: As of 2026-06-20, there is no named secular thesis driving this specific tactical trade. The investment case is not anchored to a broad macro theme (e.g., "AI in Healthcare" or "Silver Bullet for CAD") but is instead driven by the quality of the technical setup and the immediate business fundamentals. The conviction must be derived strictly from the setup quality (the forming coil) and the underlying business execution, rather than an external narrative.

3. Business Overview

Company: Heartflow, Inc. Industry: Healthcare / Medical Technology / Software & AI Business Model: Heartflow provides software and artificial intelligence designed to deliver a non-invasive solution for diagnosing and managing coronary artery disease (CAD). The company operates on a platform model where its software is deployed in healthcare accounts (hospitals, imaging centers) to analyze Coronary Computed Tomography Angiography (CCTA) data.

Key Fundamentals (as of 2026-06-20):

• Revenue Growth: The company reported revenue of $52.6 million for the three months ended March 31, 2026, compared to $37.2 million in the same period of 2025. This represents a year-over-year growth of approximately 41%.
• Product Mix: The commercial foundation remains Heartflow FFR CT Analysis, which represented 98% of total cumulative revenue as of March 31, 2026.
• Adoption Metrics: The Heartflow Platform has been used to assess CAD in more than 650,000 patients as of March 31, 2026, with 219,000 of those assessments occurring in 2025 alone.
• Installed Base: As of December 31, 2025, the platform was deployed in more than 1,465 accounts in the United States.
• Reimbursement & Coverage:
• Plaque Analysis: A new Category I CPT code (75577) took effect in January 2026. As of that date, all seven Medicare Administrative Contractors (MACs) covered Plaque Analysis. Previously, coverage was limited to five of seven MACs.
• Commercial Payors: Plaque Analysis is covered by a majority of commercial payors.
• Pipeline & Management Expectations:
• Plaque Tracker: Management anticipates launching "Plaque Tracker," their fifth product, in 2027.
• PCI Navigator: Management expects to launch "Heartflow PCI Navigator" in the second quarter of 2026. This product will enable pre-PCI assessment of coronary anatomy and lesion-specific physiology.

4. Archetype and Conviction

Archetype: Growth Leader Fit: The company fits the "Growth Leader" archetype based on the 41% year-over-year revenue growth, the expansion of the installed base to 1,465 accounts, and the successful expansion of reimbursement coverage (all 7 MACs covering Plaque Analysis). The business is scaling its core product (FFR CT) while successfully launching adjacent products (Plaque Analysis) and preparing new revenue streams (PCI Navigator).

Conviction Stack:

• Thesis Strength: Moderate. The thesis is tactical and setup-led, lacking a broad macro tailwind, but the business fundamentals are strong.
• Evidence Quality: High. The evidence is derived from primary SEC filings (Q1 2026 and Q4 2025) with clear, quantifiable metrics on revenue, patient volume, and reimbursement status.
• Structural Quality: Moderate. The setup is "forming," indicating a pause in the trend. The high ATR (5.9%) suggests the stock is volatile, which can be a double-edged sword for a forming structure.
• Setup Readiness: Partial. The coil is forming, not confirmed. The price is holding above the support level, but the breakout has not fired.
• Rerating Potential: Moderate to High. The expansion of reimbursement (all 7 MACs) and the upcoming launch of PCI Navigator (Q2 2026) provide structural catalysts for potential rerating if the breakout occurs.

5. Invalidations, Strengths, and Gaps

What Would Strengthen the Case:

• Breakout Confirmation: A daily close above the resistance level (breakout level) with volume, confirming the "forming" coil into a "confirmed" coil.
• Revenue Acceleration: Continued revenue growth exceeding the 41% YoY rate in subsequent quarters, driven by the new Plaque Analysis code and PCI Navigator launch.
• Account Expansion: An increase in the installed base beyond 1,465 accounts, indicating successful sales execution.

What Would Invalidate the Case:

• Reimbursement Rollback: Any indication that MACs or commercial payors are restricting coverage for Plaque Analysis or FFR CT.
• Product Delays: Significant delays in the launch of PCI Navigator (expected Q2 2026) or Plaque Tracker (expected 2027).

Gaps in Evidence:

• Profitability Metrics: The provided evidence focuses on revenue and adoption but does not explicitly state the company's net income, EBITDA, or cash burn status as of Q1 2026. The path to profitability is a critical missing data point for a full valuation assessment.
• Guidance: While management provided product launch dates, specific revenue guidance for the full year 2026 or 2027 is not explicitly detailed in the provided evidence snippets.
• Competitive Landscape: There is no specific evidence regarding competitive threats or market share dynamics relative to other CAD diagnostic tools.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: Revenue grew 41% YoY to $52.6M in Q1 2026; All 7 MACs now cover Plaque Analysis; Installed base reached 1,465 accounts. Key risks: Setup is forming, not confirmed; High ATR (5.9%) indicates elevated volatility; Lack of profitability data in current evidence; Product launch execution risk for PCI Navigator. Sizing hint: Position size should be conservative given the unconfirmed setup and high volatility, treating this as a partial conviction play. Expected path: Management expects PCI Navigator to launch in Q2 2026 and Plaque Tracker in 2027; structural implications suggest revenue diversification beyond FFR CT. Expected horizon: 3 to 6 months for the setup to resolve (breakout or invalidation).